UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer

This study is ongoing, but not recruiting participants.

Study NCT00146042 Information provided by University of Michigan Cancer Center

First Received: September 1, 2005 Last Updated: January 11, 2008 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	December 2008
Primary Completion Date:	December 2003 (Final data collection date for primary outcome measure)